LAUSR

Brodalumab in an Organ Transplant Recipient With Psoriasis.

Sign Up to like & get
recommendations!
0 Published in 2021 at "Cutis"

DOI: 10.12788/cutis.0167

Abstract: Immunocompromised patients, such as organ transplant recipients, require careful benefit-risk consideration when selecting a systemic agent for psoriasis. Brodalumab is an immunomodulatory biologic that binds to and inhibits IL-17RA, thereby inhibiting the actions of IL-17A,… read more here.

Keywords: organ transplant; transplant recipient; brodalumab organ; brodalumab ... See more keywords